2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1059

Increased Risk of Atrioventricular Block, Atrial Fibrillation and Pacemaker Implantation in Ankylosing Spondylitis, Undifferentiated Spondylarthritis and Psoriatic Arthritis Compared to the General Population
Abstract Number: 1060

The View of Healthy Persons on the Impact of Spondyloarthritis on Functioning and Health: Results of a Best-Worst Scaling Based on the ASAS Health Index
Abstract Number: 1061

Patients with Fibromyalgia (FM) Do Not Fulfill Classification Criteria for Axial Spondyloarthritis (axSpA) but Patients with Axspa May Fulfill Classification Criteria for FM
Abstract Number: 1062

Predictive Validity of the ASAS-Classification Criteria for Axial and Peripheral Spondyloarthritis – a Final Analysis
Abstract Number: 1063

Admissions and Readmissions of Patients with Systemic Lupus Erythematosus Is a Major Cause of Direct and Indirect Health Care Costs
Abstract Number: 1064

Feasibility and Validity of Patient Reported Outcome Measurement Information System (PROMIS) in SLE
Abstract Number: 1065

Atherosclerotic Vascular Events in a Multinational SLE Inception Cohort: Description and Predictive Risk Factors over a 15 Year Period
Abstract Number: 1066

Temporal Trends and Outcomes of Acute Myocardial Infarction in Systemic Lupus Erythematosus Hospitalizations
Abstract Number: 1067

Sex Differences in Rates of End-Stage Renal Disease and Death Among Medicaid Patients with Incident Lupus Nephritis
Abstract Number: 1068

Assessment of 10-Year Risk of Myocardial Infarction or Stroke in SLE
Abstract Number: 1069

Child’s HLA-DRB1 Genotype Increases Maternal Risk of Systemic Lupus Erythematosus: Results from the Mother-Child Immunogenetic Study in Autoimmunity
Abstract Number: 1070

CD 14(C-159T) Polymorphism and Soluble CD14 Are Associated with Increased Disease Activity and Nephritis in SLE
Abstract Number: 1071

Single-Cell RNA Sequencing of Human Podocytes, Endothelial Cells, and Tubular Cells Identifies Markers and Gene Profiles Differentiating Class IV and Class V Renal Disease in Lupus Nephritis
Abstract Number: 1072

Baseline Gene Expression Profiles in 1760 Patients from Two Phase III Trials of BAFF/BLyS Blockade in SLE
Abstract Number: 1073

B Cell Subsets Are Epigenetically and Transcriptionally Dysregulated in Systemic Lupus Erythematosus

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].